Witteveen–Kolk syndrome

Witteveen-Kolk syndrome, abbreviated WITKOS, is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous loss-of-function variants in SIN3A at chromosome 15q24.2, characterised by mild intellectual disability, developmental delay, facial dysmorphism, growth and feeding difficulties, hypotonia and variable congenital anomalies

SIN3A encodes a scaffold protein of the Sin3-histone deacetylase co-repressor complex that interacts with MeCP2 and other chromatin regulators, so haploinsufficiency perturbs transcriptional repression during cortical development and produces a chromatinopathy phenotype that overlaps with other neurodevelopmental syndromes

Most affected individuals have mild rather than severe cognitive impairment, and the combination of relative cognitive preservation with growth failure, hypotonia and distinctive facial features is what usually prompts exome or genome sequencing

Terminology and classification

• The syndrome is named after Josefine S. Witteveen and Sharon M. Kolk, whose 2016 report defined the SIN3A-related phenotype, and the short form WITKOS is used in Orphanet, OMIM and the clinical literature
• It belongs to the chromatinopathies, a group of neurodevelopmental disorders caused by germline variants in epigenetic regulators, and it is classified alongside Kleefstra syndrome, Coffin-Siris syndrome and other Sin3-HDAC-related conditions
• ICD-10 assigns Q87.8 to other specified congenital malformation syndromes and Orphanet uses ORPHA:500163, MONDO uses MONDO:0044699, OMIM uses 613406 and UMLS uses C4310804 for the same entity
• WITKOS must not be confused with the contiguous 15q24 microdeletion syndrome, which removes SIN3A together with neighbouring genes and produces a more severe and multisystem phenotype, nor with SIN3B-related disorder, which is a separate paralogopathy
• The older literature sometimes labelled SIN3A cases as atypical 15q24 deletion syndrome because the phenotypes overlap, but the 2016 discovery established SIN3A haploinsufficiency as a distinct monogenic entity
• The principal differentials are 15q24 microdeletion syndrome, Kleefstra syndrome, MECP2-related Rett spectrum disorder and Cornelia de Lange syndrome, each separated by the deleted region, the causal gene and the pattern of growth and behavioural involvement

History

• In 2016 Witteveen and colleagues identified dominant SIN3A mutations in individuals with mild intellectual disability, autism spectrum disorder, facial dysmorphism, microcephaly and short stature, and showed that the phenotype resembles that of atypical 15q24 microdeletions
• The same study used brain magnetic resonance imaging to show subtle cortical abnormalities and proposed that SIN3A haploinsufficiency impairs cortical integrity rather than producing a gross malformation, which shifted the diagnostic focus from structural imaging to molecular testing
• In 2021 Balasubramanian and colleagues published a 28-patient international series that defined the cognitive spectrum, confirmed growth and feeding problems as core features and reported 27 novel variants, 24 of which were truncating
• The 2021 series also documented that only half of assessed patients had mild intellectual disability and that a quarter had no cognitive impairment, which revised the earlier assumption that intellectual disability is universal
• Subsequent chromatinopathy reviews placed WITKOS among disorders with detectable DNA methylation episignatures, and episignature testing is now being evaluated as a functional adjunct to variant classification
• The earlier practise of diagnosing the condition only in children with severe intellectual disability was abandoned after adult and mildly affected cases were recognised, and this broadening of the phenotype is the main reason reported case numbers have increased since 2016

Epidemiology

• Fewer than 100 affected individuals had been reported by 2021, including the 28-patient international series, so the condition remains ultra-rare and no population prevalence estimate exists
• The 2021 cohort had a mean age of 8.2 years and comprised 17 males and 11 females, a sex ratio consistent with the absence of a strong sex-specific effect in autosomal dominant neurodevelopmental disorders
• Among 16 patients aged 8 years or older, 8 (50%) had mild intellectual disability, 4 (22%) had moderate disability, 1 (6%) had severe disability and 4 (25%) had no cognitive impairment, so the cognitive prognosis is better than the earlier literature suggested
• Seizures occurred in 4 of 28 patients and hypotonia in 12 of 28, making hypotonia roughly three times more common than epilepsy in this cohort and a more useful early diagnostic clue
• Among patients old enough to be assessed, three were diagnosed with autism spectrum disorder and four with attention-deficit hyperactivity disorder, and behavioural problems were reported in a minority rather than as a universal feature
• Growth and feeding difficulties are core features and were present across the cohort, with short stature and poor weight gain reported frequently enough that growth monitoring is recommended at every visit
• No founder population, ethnic predilection or environmental risk factor has been identified, and cases are reported worldwide, which is consistent with the predominance of de novo variants expected for a severe autosomal dominant neurodevelopmental disorder
• Ascertainment depends on exome and genome sequencing rather than on registries, and the condition is not notifiable, so the true prevalence is probably higher than the published case count suggests

Pathophysiology

• SIN3A is the scaffold of the Sin3-HDAC complex, which recruits histone deacetylases to promoters and enhancers and represses genes that must be silenced during neuronal differentiation and cortical layering
• SIN3A directly interacts with MeCP2, the protein mutated in Rett syndrome, so WITKOS and Rett syndrome converge on overlapping transcriptional repression pathways and may share therapeutic targets
• Most pathogenic variants are truncating or splice-site changes that reduce SIN3A protein abundance, and missense variants in the conserved protein-interaction domains can act through loss of a specific binding partner rather than through complete haploinsufficiency
• Because SIN3A regulates a large transcriptional programme rather than a single pathway, the phenotype is pleiotropic, and the same variant can produce intellectual disability, growth failure, hypotonia and congenital anomalies in different combinations
• Chromatinopathy research has identified characteristic DNA methylation episignatures in several Sin3-HDAC-related disorders, and pilot data suggest that SIN3A-related cases may also carry a detectable episignature that could support variant interpretation
• The relatively mild cognitive phenotype compared with other chromatinopathies is not explained by residual protein function alone, and modifier genes, mosaic variants and environmental factors are all being investigated as contributors to the wide expressivity

Clinical features

• Facial dysmorphism is usually present but subtle, and reported features include a broad forehead, hypertelorism, downslanting palpebral fissures, a broad nasal bridge and a thin upper lip that become more recognisable in adolescence
• Growth failure is common and manifests as short stature, poor weight gain and feeding difficulties in infancy, and some patients require nasogastric or gastrostomy feeding during early childhood
• Developmental delay affects motor and speech milestones, and hypotonia in infancy often precedes the recognition of intellectual disability, so early physiotherapy and speech therapy are usually started before molecular diagnosis
• Seizures occur in a minority and are usually responsive to standard antiseizure medication, but they can be the presenting feature and should prompt genetic evaluation when associated with hypotonia and dysmorphism
• Behavioural and psychiatric features include autism spectrum disorder, attention-deficit hyperactivity disorder, anxiety and sleep disturbance, and these often have a greater impact on family quality of life than the cognitive impairment itself
• Congenital anomalies are variable and may involve the heart, kidneys, skeleton or eyes, so a structured anomaly screen including echocardiography, renal ultrasound and ophthalmological examination is warranted at diagnosis

Diagnosis

• The diagnosis is suspected in a child with developmental delay, hypotonia, growth failure and subtle facial dysmorphism, particularly when autism spectrum disorder or seizures coexist, and it is confirmed by identifying a pathogenic SIN3A variant
• First-line testing is exome or genome sequencing, or a neurodevelopmental gene panel that includes SIN3A, because the phenotype overlaps with many other chromatinopathies and single-gene testing has low yield
• Deletion and duplication analysis by chromosomal microarray or MLPA is required in parallel because whole-gene SIN3A deletions are not detected by sequencing and because a 15q24 contiguous deletion changes the diagnosis and prognosis
• Parental testing distinguishes de novo from inherited variants, and segregation analysis is important because an affected parent has a 50% transmission risk while the recurrence risk after a de novo variant is low but not zero owing to germline mosaicism
• Baseline assessment includes growth charts, neurological examination, echocardiography, renal ultrasound, ophthalmological review, hearing test, developmental and behavioural assessment and, when seizures are suspected, electroencephalography
• The differential includes 15q24 microdeletion syndrome, Kleefstra syndrome, MECP2-related disorder, Cornelia de Lange syndrome, Coffin-Siris syndrome and other chromatinopathies, each separated by the causal gene, the deletion region and the growth and behavioural profile
• Variants of uncertain significance are common in SIN3A because the gene is large and most variants are private, and functional or episignature evidence is increasingly used to support reclassification when segregation data are unavailable

Management

• Care is coordinated by a multidisciplinary team comprising a clinical geneticist, paediatrician, neurologist, developmental paediatrician, speech therapist, physiotherapist and psychologist, as recommended by the 2021 international cohort authors
• Early developmental intervention, speech therapy and physiotherapy are started as soon as delay is recognised, because gains in communication and mobility are greatest during the preschool years and do not depend on a molecular diagnosis
• Feeding difficulties are managed with high-calorie supplementation, oral-motor therapy and, when growth failure persists, nasogastric or gastrostomy feeding, with dietitian review at every growth assessment
• Epilepsy is treated with standard antiseizure drugs such as valproate or levetiracetam according to seizure type and age, and drug-resistant seizures should prompt reassessment of the electroclinical syndrome rather than immediate escalation to polytherapy
• Attention-deficit hyperactivity disorder and anxiety are managed with behavioural strategies and, when impairment is significant, with methylphenidate or a selective serotonin reuptake inhibitor under specialist supervision
• Congenital anomalies are managed according to the organ involved, with cardiology, nephrology, orthopaedics and ophthalmology input, and surveillance intervals are set by the severity of the anomaly rather than by the genetic diagnosis alone
• Growth should be plotted at every visit, and provocation testing for growth hormone deficiency is considered only when growth velocity is persistently low and other causes have been excluded, because short stature in WITKOS is usually proportionate and not growth-hormone responsive
• Genetic counselling explains the autosomal dominant inheritance, the 50% transmission risk for an affected parent, the predominantly de novo nature of severe cases and the low but non-zero recurrence risk from germline mosaicism
• Prognosis is generally favourable for survival, and most affected adults live independently with support, but the combination of mild intellectual disability, behavioural disorder and growth failure can require lifelong educational and vocational support

Research and controversies

• Whether WITKOS should be considered a Sin3-HDAC channelopathy or a broader transcriptional repression disorder remains debated, and the answer matters because it determines which targeted compounds are tested preclinically
• DNA methylation episignature testing is promising but not yet validated for SIN3A, and its sensitivity and specificity in mildly affected adults, who are the group most likely to be missed clinically, are unknown
• The extent to which SIN3A-related intellectual disability is modifiable by early intervention is unknown, because cohorts are small, retrospectively ascertained and confounded by ascertainment of more severely affected children
• Growth hormone treatment is used in some patients with documented deficiency, but there is no evidence that it improves final height in SIN3A haploinsufficiency generally, and the risk of over-treatment in a syndromic population is a recognised concern
• International collaboration through GeneMatcher, DECIPHER and chromatinopathy registries is the main route to larger cohorts, and harmonising phenotype terms and episignature protocols is regarded as the priority for future trials